This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
3 Drugmakers in Focus After Merck's Positive COVID-19 Pill Data
by Zacks Equity Research
Here we discuss three other pharma or biotech companies with promising oral drug candidates for treating COVID-19 following Merck's (MRK) announcement of promising clinical data on its oral therapy.
Markets Wait for Major Economic and Earnings Data
by Zacks Equity Research
Markets Wait for Major Economic and Earnings Data.
Vaccine Stocks Down Following Merck's COVID-19 Pill Success
by Kinjel Shah
Stocks of several COVID-19 vaccine makers declined on Friday after Merck (MRK) released positive data for a new oral antiviral treatment for COVID-19
Topsy-Turvy Stock Markets to Start a New Week
by Mark Vickery
After 1% gains on Friday, which followed -2% losses for the full week, the Dow, S&P 500 and Nasdaq are all selling off again early Monday.
Stock Market News for Oct 4, 2021
by Zacks Equity Research
U.S. stocks rebound on Friday, the first trading day of the fourth quarter of 2021.
ETFs to Play as Merck Shares Surge on COVID Treatment News
by Sanghamitra Saha
Merck & Co shares gained 8.4% on Oct 1, 2021 on news of success in its COVID treatment.
Merck (MRK) Moves 8.4% Higher: Will This Strength Last?
by Zacks Equity Research
Merck (MRK) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Core PCE Inflation Stays at Record-High in August
by Zacks Equity Research
Core PCE Inflation Stays at Record-High in August.
Merck (MRK) Develops Pill to Lessen Covid Symptoms
by Mark Vickery
Results of a trial developed with Cambridge, MA-based Ridgeback Biotherapeutics are positive for an oral antiviral treatment for Covid-19.
Pharma Stock Roundup: MRK to Buy XLRN, ABBV Gets FDA Nod for Migraine Drug & More
by Kinjel Shah
Merck (MRK) offers to buy Acceleron Pharma for about $11.5 million. FDA approves AbbVie's (ABBV) new migraine drug, Qulipta.
Merck (MRK) to Acquire Acceleron, Build Rare Disease Portfolio
by Zacks Equity Research
Merck (MRK) is set to acquire rare diseases-focused company Acceleron Pharma for $11.5 billion and gain access to its promising phase III candidate.
AstraZeneca (AZN) Up on Enhertu, Imfinzi Cancer Data at ESMO (Revised)
by Zacks Equity Research
AstraZeneca's (AZN) Enhertu reduces the risk of disease progression by 72% in HER2-positive metastatic breast cancer. Imfinzi plus chemotherapy triples patient survival at three years in ES-SCLC.
FDA Accepts Bristol Myers (BMY) sBLAs for Opdivo Combo for ESCC
by Zacks Equity Research
The FDA accepts Bristol Myers' (BMY) sBLAs for Opdivo-based combinations as a potential treatment for esophageal squamous cell carcinoma.
Merck (MRK) Keytruda Meets Hepatocellular Carcinoma Study Goal
by Zacks Equity Research
Merck's (MRK) Keytruda achieves both primary and secondary endpoints in a phase III study evaluating the drug in patients with advanced hepatocellular carcinoma.
Acceleron (XLRN) Stock Up on Takeover Rumors for $11 Billion
by Zacks Equity Research
Acceleron (XLRN) up on rumors of a potential acquisition by a pharma giant for $11 billion or $180 per share.
Merck (MRK) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Merck (MRK) closed the most recent trading day at $73.36, moving -0.34% from the previous trading session.
AstraZeneca, Merck's Lynparza Prostate Cancer Study Meets Goal
by Zacks Equity Research
AstraZeneca (AZN) and Merck (MRK) announce that their PARP inhibitor Lynparza succeeds in meeting the primary endpoint in a late-stage study, evaluating it in first-line castration-resistant prostate cancer patients.
BELLUS (BLU) Completes Enrollment in Two Mid-Stage Studies
by Zacks Equity Research
BELLUS (BLU) completes enrollment in the mid-stage studies for refractory chronic cough and chronic pruritus associated with atopic dermatitis.
Nektar (NKTR) Signs Deals With Pfizer, Merck KGaA for NKTR-255
by Zacks Equity Research
Nektar (NKTR) signs a collaboration deal with Pfizer and Merck KGaA to develop a combination of its NKTR-255 with the latter's Bavencio for treating urothelial carcinoma.
AstraZeneca (AZN) Up on Enhertu, Imfinzi Cancer Data at ESMO
by Zacks Equity Research
AstraZeneca's (AZN) Enhertu reduces the risk of disease progression by 72% in HER2-positive metastatic breast cancer. Imfinzi plus chemotherapy triples patient survival at three years in ES-SCLC.
Bristol Myers (BMY) Opdivo-Relatlimab Combo Gets Priority Review
by Zacks Equity Research
Bristol Myers (BMY) application for fixed-dose combination of LAG-3-blocking antibody relatlimab and immuno- oncology Opdivo gets priority review in the United States.
Merck (MRK) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Merck (MRK) closed at $71.93 in the latest trading session, marking a +0.35% move from the prior day.
Merck (MRK) Keytruda Gets CHMP Nod for Severe Breast Cancer
by Zacks Equity Research
The CHMP recommends an approval of Merck's (MRK) Keytruda combo for the treatment of patients with metastatic triple-negative breast cancer.
Mirati (MRTX) Reports Positive Data From Colorectal Cancer Study
by Zacks Equity Research
Mirati (MRTX) reports positive data from a cohort of the phase I/IIstudy evaluating its KRAS inhibitor adagrasib in patients with KRAS G12C-mutated colorectal cancer.
Bristol Myers' (BMY) Opdivo Combo for Gastric Cancer Gets CHMP Nod
by Zacks Equity Research
Bristol Myers' (BMY) Opdivo, in combination with chemotherapy, gets positive CHMP recommendation by the EMA for treating adults with gastric cancer, among others.